These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2967622)

  • 1. [Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Isurugi K; Niijima T; Aso Y; Araki T
    Hinyokika Kiyo; 1988 Feb; 34(2):369-82. PubMed ID: 2967622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Nihsijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Nov; 34(11):2059-66. PubMed ID: 2977261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer].
    Kaufmann M; Schmid H; Kiesel L; Klinga K
    Geburtshilfe Frauenheilkd; 1988 Jul; 48(7):528-32. PubMed ID: 2975241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
    Lunglmayr G
    Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.